MedTrace Logo

Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?

NCT06170164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2023-12-14

No results posted yet for this study

Summary

The role of PET/CT with Choline in the restaging of prostatic disease is now universally recognized, and its use has become routine in numerous centers in Italy and abroad. The indication for the test is provided exclusively by an increase in PSA. It was interesting to understand whether these prognostic factors have an influence on the probability of detecting disease by PET with Choline to identify patients who have a greater probability of benefiting from the use of this method with the possibility of identifying the disease in earlier stages.

Conditions

Interventions

DIAGNOSTIC_TEST

Diagnostic accuracy

The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.

Sponsors & Collaborators

  • IRCCS San Raffaele

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-08
Primary Completion
2015-11-25
Completion
2015-11-25

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06170164 on ClinicalTrials.gov